Abstract-Proadrenomedullin N-terminal 20 peptide ; ARLDVASEFRKKWNKWALSR-amide) is a potent hypotensive and catecholamine release-inhibitory peptide released from chromaffin cells. We studied the mechanism of PAMP action and how its function is linked to structure. We tested human PAMP-[1-20] on catecholamine secretion in PC12 pheochromocytoma cells and found it to be a potent, dose-dependent (IC 50 Ϸ350 nmol/L) secretory inhibitor. Inhibition was specific for nicotinic cholinergic stimulation since PAMP-[1-20] failed to inhibit release by agents that bypass the nicotinic receptor. Nicotinic cationic ( 22 Na ϩ , 45 Ca 2ϩ ) signal transduction was disrupted by this peptide, and potencies for inhibition of 22 Na ϩ uptake and catecholamine secretion were comparable. Even high-dose nicotine failed to overcome the inhibition, suggesting noncompetitive nicotinic antagonism. N-and C-terminal PAMP truncation peptides indicated a role for the C-terminal amide and refined the minimal active region to the C-terminal 8 amino acids (WNKWALSR-amide), a region likely to be ␣-helical. PAMP also blocked (EC 50 Ϸ270 nmol/L) nicotinic cholinergic agonist desensitization of catecholamine release, as well as desensitization of nicotinic signal transduction ( 22 Na ϩ uptake). Thus, PAMP may exert both inhibitory and facilitatory effects on nicotinic signaling, depending on the prior state of nicotinic stimulation. PAMP may therefore contribute to a novel, autocrine, homeostatic (negative-feedback) mechanism controlling catecholamine release. (Hypertension. 1998;32:907-916.)
A drenomedullin is a novel hypotensive peptide originally isolated from human pheochromocytoma as a cAMPelevating agent. 1 The 52-amino acid human adrenomedullin shares sequence homology with the calcitonin gene-related peptide and pancreatic amylin family. 1 cDNA sequences of rat, pig, and human forms reveal that preproadrenomedullin consists of 185 amino acids, with 3 sites of paired basic amino acids as targets for prohormone-processing proteolytic cleavage. [1] [2] [3] Excision of the signal peptide between amino acids Thr 21 and Ala 22 in preproadrenomedullin yields a proadrenomedullin propeptide of 164 amino acids.
Proadrenomedullin N-terminal 20 peptide (PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ; ARLDVASEFRKKWNKWALSR-amide) is liberated from proadrenomedullin by proteolytic cleavage at the first group of basic amino acids (Gly 42 Lys 43 Arg 44 ), after which PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] is posttranslationally amidated at its carboxy terminus in response to the Gly signal for the enzyme peptidylglycine ␣-amidating monooxygenase. cDNA sequences of rat, pig, and human forms show 80% sequence identity of the PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] region (Table 1) , and 12 amino acids at the C-terminus are conserved in all 3 species [1] [2] [3] (Table 1 ). PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] is found in plasma, adrenal medulla, right atrium, kidney, and brain 4, 5 and exerts hypotensive activity in the rat and cat. 1,6 -12 Plasma levels of PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] are elevated in human disease states such as essential hypertension, 13 renal failure, 14 and congestive heart failure, 15 as well as in the spontaneously hypertensive rat. 16 While adrenomedullin decreases vascular resistance by a direct action on vascular smooth muscle or by releasing nitric oxide from the endothelium, [17] [18] [19] [20] PAMP may induce vasodilation by a variety of site-or species-dependent mechanisms: inhibition of norepinephrine release from adrenergic nerve endings in the mesenteric vascular bed of the rat, 5, 21 direct or tone-dependent vasodilation in the hindquarters vascular bed of the rat, 9 or cAMP-mediated vasodilator activity in the mesenteric and hindlimb vascular beds of the cat. 10, 22 Recently, PAMP- [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] (a carboxy-terminal fragment of PAMP) has been identified in porcine adrenal medulla and causes hypotension on intravenous injection in the rat. 7 Synthetic human PAMP- [12] [13] [14] [15] [16] [17] [18] [19] [20] is also a vasodepressor in the rat and cat. 8 In bovine chromaffin cells, PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] has been reported to inhibit nicotinic agonist-induced catecholamine secretion 23 and synthesis 24 and nicotinic agonist-induced Na ϩ and Ca 2ϩ influx. 23, 25 However, the precise mechanism or site of PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] action remains in doubt, with different reports implicating the nicotinic cholinergic receptor 23, 25 or an alternative mechanism involving a G protein-coupled receptor inhibiting voltage-gated calcium currents. 26 We examined the effects of PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] on catecholamine secretion from rat pheochromocytoma PC12 cells, determining the crucial active residues in its sequence. We also studied its actions on signal transduction mechanisms for catecholamine release and uncovered a novel effect on nicotinic cholinergic desensitization. Our results reveal that PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] inhibits catecholamine secretion (IC 50 Ϸ350 nmol/L), acting in a noncompetitive manner specifically at the nicotinic cholinergic receptor; in addition, PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] inhibits the desensitization of catecholamine release evoked by nicotinic agonists. Peptide deletion studies establish that the carboxy-terminal domain of PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] is crucial to its antisecretory activity.
Methods

Cell Culture
Rat PC12 pheochromocytoma cells 27 (at passage 8, obtained from Dr David Schubert, Salk Institute, La Jolla, Calif) were grown at 37°C/6% CO 2 , in 10-cm plates or 6-well plates, in DME/highglucose medium supplemented with 5% fetal bovine serum, 10% horse serum, 100 U/mL penicillin, and 1% penicillin/streptomycin (100% stocks were 10 000 U/mL penicillin G and 10 000 g/mL streptomycin sulfate; Life Technologies, Inc). 28 In some experiments, cells were pretreated with pertussis toxin (100 ng/mL, 16 hours).
29
Secretagogue-Stimulated Release of Norepinephrine
Secretion of norepinephrine was monitored as previously described. 28 
Synthetic Peptides
PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] or its analogues were synthesized at 10 to 100 mol scale by the solid-phase method 30 with t-boc or f-moc protection chemistry and then purified to Ͼ95% homogeneity by reversedphase high-pressure liquid chromatography on C-18 silica columns, with monitoring of A 280 (aromatic rings) or A 214 (peptide bonds). Authenticity and purity of peptides were verified by rechromatography, as well as by electrospray-ionization or matrix-assisted laser desorption ionization (MALDI) mass spectrometry or amino acid composition. For some experiments, small-scale (1 mol) peptide syntheses were accomplished by pin technology (Chiron Mimotopes), after which peptides were cleaved from the resin and washed.
Neuronal Differentiation of PC12 Cells With Nerve Growth Factor
PC12 cells were split to 50% confluence and treated with nerve growth factor (NGF) (2.5S, murine, natural, 100 ng/mL; GIBCO-BRL). The medium was changed every other day with NGF addition to the new medium. After 7 days of treatment, the neurite-bearing cells were used for secretion studies, as described above.
Na
؉ Uptake by PC12 Cells 22 Na ϩ uptake was studied as described by Amy and Kirshner 31 with minor modifications. Before experiments, PC12 cells were washed twice with 50 mmol/L Na ϩ -sucrose media containing 50 mmol/L NaCl, 187 mmol/L sucrose, 5 mmol/L KCl, 2 mmol/L CaCl 2 , and 5 mmol/L HEPES adjusted to pH 7.4 with NaOH. To measure 22 Na ϩ influx, this medium was then supplemented with 5 mmol/L ouabain (to prevent active extrusion of newly taken-up 22 Na ϩ from cells) and 1.5 Ci/mL of 22 NaCl. Incubation was performed at 22°C for 5 minutes, in the presence or absence of secretagogues, and then the cells were washed within 10 seconds with 3 changes (1 mL each) of 50 mmol/L Na ϩ -sucrose media with 5 mmol/L ouabain. The cells were lysed (see above), and 22 Na ϩ in the cell lysate was measured in a gamma counter (LKB 1274 RIAGAMMA, Wallac Inc). The data were expressed as disintegrations per minute per well.
Ca 2؉ Uptake by PC12 Cells
Cells were seeded onto poly-D-lysine-coated 6-well polystyrene culture dishes 2 days before assay. Cells were rinsed with 1 mL of release buffer and preincubated with 1 mL of release buffer for 30 minutes at 37°C. Then the cells were incubated for 5 minutes at 37°C in 1 mL of release buffer (without unlabeled calcium) containing 2 Ci of 45 Ca 2ϩ (14.95 mCi/mg, DuPont/NEN). The drugs tested were present in the release buffer during the 1-minute incubation period. Calcium uptake was stopped abruptly after 1 minute by inversion of the plate to decant all 6 wells simultaneously, followed promptly by addition of 2 mL of ice-cold release buffer containing 1 mmol/L LaCl 3 ; the nonselective calcium channel blocker La 3ϩ terminates further uptake of extracellular labeled calcium. 32 The culture dishes were then rinsed twice with ice-cold release buffer. To cells in each well, 1 mL of cell lysis buffer was added and collected for liquid scintillation counting. The data were expressed as disintegrations per minute per well.
Structure Predictions
Secondary structure of PAMP was first predicted by the empirical statistical Chou-Fasman 33 or Robson-Garnier 34 algorithms with the use of the program MacVector (version 5.0.2; Oxford Molecular Group PLC). Secondary structure predictions for amphiphilicity, in which hydrophobic moment plots were used, 35 were also done on MacVector.
Homology modeling allowed prediction of 3-dimensional structure on the basis of known (x-ray crystallographic-or nuclear magnetic resonance-derived) structures of remote homologues in the Protein Data Bank 36 (PDB). Remote homologues were detected by the method of prediction-based threading 37 on the EMBL Web server. 38 ␣-Helical structures were created in the graphic program Fold-It (light) (version 4.0.7; Reference 39 and jean-claude.jesior@imag.fr), and the PDB format (x, y, z coordinates) fileswere imported into the program CS Chem3D Pro (version 3.2; CambridgeSoft) for energy minimization by molecular mechanics with the use of the MM2 force field and the method of steepest descent. The MM2 force field includes both covalent (bond stretching, bending, and torsion) and noncovalent (Van der Waals, charge-charge, charge-dipole, and dipole-dipole) terms. 
Results
PAMP as a Noncompetitive Nicotinic Cholinergic Antagonist
To test whether PAMP exerted its nicotinic antagonist action by a competitive or noncompetitive means, we stimulated PC12 cells with a spectrum of nicotine doses ( 
PAMP Biological Activity Resides Toward Its C-Terminus
To define active residues within the PAMP- 
PAMP Inhibition Specific for Nicotinic Cholinergic Stimulation of Catecholamine Secretion
In addition to stimulation of the physiological (nicotinic cholinergic) secretory pathway (by nicotine, 60 mol/L), we tested several secretagogues that act at stages in the pathway later than the nicotinic receptor (Table 2) (Table 2) and not when secretion was caused by agents acting later (ie, distal to the nicotinic cholinergic receptor) in the secretory pathway ( Table 2) .
Stimulation of P 2x purinergic receptors causes catecholamine secretion from PC12 cells. 41 Since P 2x receptors and nicotinic cholinergic receptors are members of the same superfamily of extracellular ligand-gated cation channels, 41 we tested the effect of PAMP on the function of this receptor, as well. Although the somewhat selective P 2x antagonist reactive blue 2 41 substantially inhibited ATPstimulated catecholamine release (from 52.1Ϯ0.09% to 20.6Ϯ1.49% release), PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] was without effect on this ligand-receptor system (Table 2) . Figure 5A ). To test the specificity of PAMP action on nicotinic signaling pathways, we studied the effects of PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide on 45 Ca 2ϩ uptake into PC12 cells induced by nicotine (60 mol/L) or by membrane depolarization (55 mmol/L KCl), which opens voltage-gated calcium channels. While PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide completely abolished nicotine-induced uptake of 45 Ca 2ϩ , it failed to block 45 Ca 2ϩ uptake when voltage-gated calcium channels were directly opened by membrane depolarization ( Figure 5B ).
PAMP Effect on
Testing Involvement of Inhibitory G Proteins in the PAMP Effect on PC12 Cells
To test whether the effect of PAMP on nicotine-induced norepinephrine release might be mediated by inhibitory G proteins, we pretreated PC12 cells with the G i /G o inactivator pertussis toxin (100 ng/mL, 16 hours 29 ) and then tested the effects of PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide on nicotineinduced catecholamine release. No effect of pertussis toxin on the PAMP-[1-20]-amide antisecretory effect was noted (data not shown). Similar studies were performed in NGF (100 ng/mL for 7 days)-treated PC12 cells, and we found no difference between pertussis toxin-pretreated or control 
, either alone or in combination with human PAMP (10 mol/L), and harvested after 30 minutes for measurement of norepinephrine secretion. The effect of ATP was inhibited (to 39%) by the P 2ϫ receptor antagonist reactive blue 2 (100 mol/L).
PC12 cells in inhibition of catecholamine release by PAMP-[1-20]-amide (data not shown).
Role of PAMP Truncation Peptides in Inhibition of Catecholamine Secretion by PAMP-[1-20]-amide
We tested whether any of these functionally inactive PAMP truncation peptides antagonize the action of full-length 
PAMP Inhibition of Nicotinic Cholinergic Desensitization of Catecholamine Release
Repeated or prolonged exposure of chromaffin cells to nicotinic cholinergic agonists results in diminution of subsequent catecholamine secretion responses to nicotinic rechallenge. 42 To determine whether PAMP influences nicotinic desensitization, we exposed PC12 cells to nicotine (10 mol/L) for 10 minutes, either alone or in combination with ascending doses (0. 
PAMP Blockade of Nicotinic Desensitization of 22 Na
؉ Uptake, the First Step in Nicotinic Signal Transduction
To test whether PAMP blockade of desensitization of catecholamine release is achieved at the most proximal step in nicotinic cholinergic signaling, we studied the effect of PAMP on 22 Na ϩ uptake during nicotinic rechallenge. In the initial incubation (incubation I), PC12 cells were exposed to nicotine (10 mol/L; 10 minutes), nicotine plus PAMP-[10-20]-amide (10 mol/L), or buffer alone. After washout, the same groups were exposed to nicotine (10 mol/L; 10 minutes) for measurement of cellular 22 Na ϩ uptake. Prior exposure to nicotine alone caused 82.1% diminution of 22 Na ϩ uptake on reexposure to nicotine, but prior coincubation with PAMP- [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide (10 mol/L) completely reversed this effect (returning to 100.1% of secretion achieved without prior nicotine exposure; Figure 7B ).
PAMP Structure
Both the Chou-Fasman 33 and Robson-Garnier 34 algorithms predicted an ␣-helical conformation for PAMP. The ␣-helix displayed no amphiphilicity on hydrophobic moment plot. 35 Twenty known-structure remote homologues of PAMP were detected by the threading algorithm, 37 with up to 30% (range, 15% to 30%) pairwise sequence identity with PAMP and with Z alignment scores up to 1.83 (range, 1.34 to 1.83). The homologous regions were found in the following PDB entries: 1bct, 4 gpb, 3 mdd, 1oct, 7ccp, 1hlb, 1 mgn, 2hmz, 1trk, 3ccp, 2cyp, 1ses, 1tph, 2spo, 2 mge, 1hle (4 regions), and 2ccy. Each of these homologous regions was predominantly ␣-helical in the homologue of known structure, especially toward the C-terminus of each segment. An ␣-helical conformation of the PAMP sequence was therefore created and subjected to energy minimization; after 261 iterations in the MM2 force field, the root mean square gradient (slope) minimized at 0.088, indicating a local energy minimum. The resulting ␣-helix is displayed in side ( Figure 8A ) and axial ( Figure 8B ) views.
Discussion
The present findings reveal that PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide is a potent inhibitor (IC 50 Ϸ0.35 mol/L) of catecholamine secretion from PC12 pheochromocytoma cells, in keeping with an earlier report 23 in bovine chromaffin cells (IC 50 Ϸ1.6 mol/L). Our results also indicate that this inhibition is specific for the nicotinic cholinergic pathway, since inhibition did not occur after secretory stimulation by a variety of maneuvers that bypass the nicotinic receptor (Table 2) , including membrane depolarization, calcium ionophore, or alkalinization of secretory vesicles. Purinergic P 2x ionotropic receptors, which cause secretion in response to ATP, 41 were not inhibited by PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide (Table 2 ). Since P 2x and nicotinic receptors are members of the same superfamily of extracellular ligand-gated cation channels, 41 the specificity of Figure 5B ), but only when such entry was triggered by nicotinic stimulation and not when triggered by membrane depolarization (Figure 5B ), which opens calcium channels at a signal transduction step distal to nicotinic stimulation. 40 In NGF-differentiated PC12 cells, Takano et al 26 described a very different action of PAMP on Ca 2ϩ influx: PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide inhibited divalent cation inward currents through N-type Ca 2ϩ channels, and this inhibition could be abolished by pretreatment with pertussis toxin, suggesting an action of PAMP on a receptor utilizing a pertussis toxin-sensitive G protein. 26 Therefore, we also examined whether pertussis toxin-sensitive G proteins mediate PAMP antisecretory activity in either normal PC12 cells, which express mainly L-type Ca 2ϩ channels, 43 or in NGF-treated PC12 cells, which express N-type Ca 2ϩ channels. 43 The catecholamine release-inhibitory action of PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide was not influenced by pertussis toxin in either normal (data not shown) or NGF-treated (data not shown) PC12 cells. Thus, in this PC12 cell system, the PAMP effect to inhibit catecholamine release can be entirely accounted for by actions on the nicotinic receptor. Ϸ0.12 mol/L); thus, residues crucial for PAMP activity reside toward its C-terminus ( Figures 3A and B) , while N-terminal residues 1 through 9 (ARLDVASEF) may actually be modestly inhibitory to the overall nicotinic cholinergic actions of PAMP. Even the 8 -amino acid peptide PAMP- [13] [14] [15] [16] [17] [18] [19] [20] -amide (WNKWALSR-amide) retained substantial potency (IC 50 Ϸ0.53 mol/L; Figure 3A) . The enhanced potency of PAMP- [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide (IC 50 Ϸ0.045 mol/L; RKKWNKWALSR-amide; Figure 5A ) may be of importance in vivo, since PAMP [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] has been identified in the porcine adrenal medulla and exhibits a hypotensive effect on intravenous injection in the rat. 7 In addition, the synthetic C-terminal PAMP fragment PAMP- [12] [13] [14] [15] [16] [17] [18] [19] [20] -amide (KWNKWALSR-amide) is also a vasodepressor in the rat and cat. 8 Of note, the 12 functionally crucial amino acids at the C-terminus of PAMP are completely conserved in all mammalian species thus far studied (rat, pig, and human; Table 1 ).
Two different lines of evidence (empirical statistical algorithms 33, 34 and knowledge-based homology modeling 37 ) predicted an ␣-helical structure for PAMP (Figure 8 ). The antisecretory activity of PAMP is retained in PAMP- [13] [14] [15] [16] [17] [18] [19] [20] (WNKWALSR-amide; IC 50 Ϸ0.045 mol/L; Figure 5 ). Since each hydrogen-bonding turn of an ␣-helix comprises Ϸ3.5 amino acid residues, it is conceivable that an active ␣-helical conformation might not be sustainable with Ͻ2 turns of helix, although peptides of up to 15 to 20 residues in length are typically required for exhibition of a preference for adopting stable helical structures in solution. 45 Both substance P 42 and PAMP ( Figure 7A ) require C-terminal amidation for their effects, and each blocks nicotinic desensitization of both catecholamine release ( Figure 7A ) and 22 Na ϩ uptake ( Figure 7B ). Both of these peptides are quite basic in amino acid composition (PAMP- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , pI Ϸ11.14; PAMP- [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , pI Ϸ12.49; substance P, pI Ϸ11.14), although they otherwise do not share common primary structure (for substance P: RPKPQQFFGLM-amide).
Proadrenomedullin fragments may have complex effects on blood pressure. Even the vascular actions of adrenomedullin are multiple: while adrenomedullin itself (adrenomedullin ) is a vasodilator, the adrenomedullin fragments adrenomedullin , adrenomedullin 16 -21 , adrenomedullin [15] [16] [17] [18] [19] [20] [21] [22] , and adrenomedullin 16 -31 actually have pressor effects, in species-specific fashion, 22 and the pressor effects are abrogated by sympatholytic maneuvers such as ␣-adrenergic blockade, 46, 47 catecholamine storage depletion, 46, 47 or adrenalectomy. 46 Since the pressor effect of adrenomedullin [15] [16] [17] [18] [19] [20] [21] [22] is not abrogated by the nicotinic cholinergic antagonist hexamethonium, 46 this response is also unlikely to be influenced by the nicotinic antagonist activity of PAMP (the present report).
In conclusion, PAMP not only inhibits nicotinic cholinergic-stimulated chromaffin cell catecholamine release but also antagonizes the desensitization of catecholamine release induced by nicotine. These 2 effects of PAMP are selective for the physiological (nicotinic cholinergic agonist) stimulus to chromaffin cell secretion. At the nicotinic receptor, the inhibition is noncompetitive with agonist. The inhibition specifically impairs nicotinic cationic (Ca 2ϩ and Na ϩ ) signal transduction. Since PAMP is coreleased with catecholamines, 23 it may therefore contribute to a novel, autocrine homeostatic (negative-feedback) mechanism controlling catecholamine release from chromaffin cells (Figure 9 ). We speculate that PAMP blockade of nicotinic desensitization of catecholamine release may be advantageous to an organism, particularly during circumstances of heightened sympathetic outflow, a setting in which this action of PAMP might sustain catecholamine release.
